FO 152
Latest Information Update: 17 Feb 1995
Price :
$50 *
At a glance
- Originator Daiichi Fine Chemical
- Developer Daiichi Fine Chemical; Sankyo
- Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Feb 1995 Discontinued-II for Cancer in Japan (Injection)